Electromed: Some Short Term Gain But I Fear Long Term Pain

Electromed (ELMD) has delivered strong revenue growth and margin improvement, but faces a highly competitive, fragmented market for its SmartVest product. ELMD lacks a durable moat, with rivals like Tactile Medical and Baxter showing stronger brand recognition, technological advantages, and higher recent growth rates. Scientific evidence questions the comparative efficacy of HFCWO versus alternative airway clearance therapies, undermining the long-term growth thesis for SmartVest.

Seeking Alpha • 21 hours ago

3 Medical Instrument Stocks Banking on GenAI to Tackle Industry Woes

ISRG, EW and ELMD tap GenAI to enhance diagnostics and workflows, even as MedTech faces cost pressures, data risks and macro headwinds.

Zacks Investment Research • Feb 23, 2026

Here is Why Growth Investors Should Buy Electromed (ELMD) Now

Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Feb 12, 2026

Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript

Electromed, Inc. (ELMD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Feb 11, 2026

Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter.

Business Wire • Feb 10, 2026

Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates

Electromed, Inc. (ELMD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago.

Zacks Investment Research • Feb 10, 2026

Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 second quarter ended December 31, 2025, on Tuesday, February 10, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may partic.

Business Wire • Jan 27, 2026

5 Highly Efficient Stocks That Stand Out on Key Profitability Ratios

United Natural Foods leads a screen of five efficient stocks that beat peers on key ratios, highlighting names investors may consider for stronger returns.

Zacks Investment Research • Jan 7, 2026

Wall Street Analysts See a 36.98% Upside in Electromed (ELMD): Can the Stock Really Move This High?

The consensus price target hints at a 37% upside potential for Electromed (ELMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 1, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Electromed (ELMD)

Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Dec 1, 2025